Thermo Fisher Scientific (TMO) analysis

Loading the Vaultflake…

Health is the debt of a lab supplier, not of the customer's drug. Quality separates the reagent margin, which repeats, from the instrument and the manufacturing contract. Growth follows the customer's research spending, not a unique shop. P/E is read against a year of heavy research, not against that peak. Shareholder return, if any, comes out of that cash. Do not read it as a supplier change that cannot happen.

The P/E of a year of heavy lab spending is not normal earnings. EV/EBITDA is read without treating the manufacturing contract as assured revenue. Do not use a drugmaker's multiple, which sells the drug, as if the instrument and the patent were the same book. A dash if the TMO cache is cold.

Limits of this report

Not advice on Thermo Fisher. Vaultflake does not describe how the customer's drug is made and does not treat the catalog as irreplaceable. Read the filings. The table is a snapshot, not a target price.

Questions from this report